Q3 2018

sabe_nada · 2018-10-23T17:50:00-03:00

Third quarter 2018 results: Revenue of $853 million, a 20% increase compared to $714 million in the third quarter of 2017 GAAP net income attributable to Illumina stockholders for the quarter of $199 million, or $1.33 per diluted share, compared to $163 million, or $1.11 per diluted share, for the third quarter of 2017 Non-GAAP net income attributable to Illumina stockholders for the quarter of $227 million, or $1.52 per diluted share, compared to $163 million, or $1.11 per diluted share, for the third quarter of 2017 (see the table entitled “Itemized Reconciliation Between GAAP and Non-GAAP Net Income Attributable to Illumina Stockholders” for a reconciliation of these GAAP and non-GAAP financial measures) Cash flow from operations of $292 million compared to $235 million in the third quarter of 2017 Free cash flow (cash flow from operations less capital expenditures) of $228 million for the quarter, compared to $153 million in the third quarter of 2017 Press Release

@MarkFord
em 24/10/2018 09:03

A Illumina Inc. (NASDAQ: ILMN) divulgou seu resultado trimestral na terça-feira, 23 de outubro. A empresa reportou lucro de US $ 1,52 por ação no trimestre, superando a estimativa de consenso da Thomson Reuters, que era de US $ 1,26, por US $ 0,26. A companhia reportou receita de US $ 853 milhões no trimestre, ao passo que a estimativa de consenso era de US $ 825,65 milhões. A Illumina teve um retorno sobre o patrimônio líquido de 26,64% e uma margem líquida de 20,88%. A receita trimestral da empresa cresceu 19,5% em relação ao ano anterior. Durante o mesmo trimestre do ano anterior, a empresa registrou US $ 1,11 EPS.

NASDAQ:ILMN - Stock Price, News, & Analysis for Illumina

#1 de 3

@MarkFord
em 24/10/2018 09:04

“Illumina’s strong performance in the third quarter of 2018 reflected growth across our sequencing and arrays portfolios,” said Francis deSouza, President and CEO. “Sequencing system revenue of $138 million was the strongest since 2015, reflecting strong demand within our sequencing family from the NovaSeq, the most powerful and flexible sequencer ever, to the iSeq, our most accessible and easiest-to-use sequencer.”
Press Release

#2 de 3

@MarkFord
em 06/11/2018 11:29

Where Will Illumina, Inc. Be in 10 Years?

Theres a lot of growth in the future for this genomic-sequencing pioneer.

Where Will Illumina, Inc. Be in 10 Years? -- The Motley Fool

#3 de 3